Literature DB >> 30468734

Non-invasive dynamic monitoring initiation and growth of pancreatic tumor in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model.

Su Hu1, Liang Pan2, Junjie Shangguan3, Matteo Figini3, Aydin Eresen3, Chong Sun4, Bin Wang5, Quanhong Ma3, Chunhong Hu6, Vahid Yaghmai7, Yuri Velichko7, Jia Yang8, Zhuoli Zhang9.   

Abstract

The LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mouse is one of the most widely used transgenic models to evaluate tumor characteristics and to develop novel therapies for pancreatic ductal adenocarcinoma (PDAC). There is no report of the effective systemic evaluation of longitudinal KPC tumor imitation and growth. Therefore, we aimed to characterize the initiation and progression of pancreatic cancer in KPC mice using longitudinal multiparametric magnetic resonance imaging (MRI) approaches and overall survival. Ten KPC mice were used to develop spontaneous PDAC and monitored by MRI. Tumor growth was evaluated using weekly acquired MRI data. The relationship between diffusion-weighted MRI (DW-MRI) imaging biomarkers (apparent diffusion coefficient - ADC) and tumor fibrosis measurement by pathological methods was assessed by Pearson correlation coefficient. Six KPC mice developed spontaneously pancreatic tumors at the age of 20.0 ± 2.9 weeks with a relatively short life span (6.8 ± 1.8 weeks). The tumors could be detected by MRI with a minimum diameter of 3.88 ± 1.18 mm (range, 2.18-5.20 mm), showing a rapid growth curve according to both the longest diameter (1.63 ± 0.52 mm/week) and tumor volume (148.77 ± 80.87 mm3)/week. Pathological results confirmed that the tumors display histopathological features of human pancreatic cancer. A strong correlation between ADC values and fibrosis measurements was observed (R = -0.825, P = .043). Our results show that the initiation and progression of pancreatic tumor in KPC mice can be evaluated by longitudinally non-invasive dynamic MRI approaches. The findings will be the fundamental KPC background data for developing novel therapeutic approaches, in particular for evaluation of response to novel treatments.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  KPC mouse model; Magnetic resonance imaging; Pancreatic cancer; Tumorigenesis

Mesh:

Year:  2018        PMID: 30468734     DOI: 10.1016/j.jim.2018.11.009

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma.

Authors:  Jia Yang; Su Hu; Junjie Shangguan; Aydin Eresen; Yu Li; Liang Pan; Quanhong Ma; Yuri Velichko; Jian Wang; Chunhong Hu; Vahid Yaghmai; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

2.  Dinaciclib prolongs survival in the LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma.

Authors:  Jia Yang; Su Hu; Junjie Shangguan; Aydin Eresen; Yu Li; Quanhong Ma; Vahid Yaghmai; Al B Benson Iii; Zhuoli Zhang
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

3.  Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a KrasLSL-G12D p53LSL-R172H Pdx1-Cre mouse model.

Authors:  Su Hu; Jia Yang; Junjie Shangguan; Aydin Eresen; Yu Li; Quanhong Ma; Vahid Yaghmai; Yuri Velichko; Chunhong Hu; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.